1 |
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine. 2006;3(11):e442(2011-2030).
|
2 |
National Heart L, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Maryland: US deparment of Health and H㎛an Services, Public Health Service, National Institutes of Health, 2009.
|
3 |
KOSTAT. Causes of Death Statistics in 2010. 2011.
|
4 |
Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, Oh Y-M, Lee S-D, Lee JH, Kim K-J, Kim J-H, Park YB. Health care use and economic burden of patients with diagnosedchronic obstructive pulmonary disease in Korea. The International Journal of Tuberculosis and Lung Disease, 2014;18(6):737-743.
DOI
|
5 |
Shergis JL, Di YM, Zhang AL, Vlahos R, Helliwell R, Ye JM, Xue CC. Therapeuticpotential of Panax ginseng and ginsenosides in the treatment of chronic obstructive pulmonary disease. Complementary Therapies in Medicine, 2014;22: 944-953.
DOI
|
6 |
Lee JH, Min DS, Lee CW, Song KH, Kim YS, Kim HP. Ginsenosides from Korean Red Ginseng ameliorate lung inflammatory responses: inhibition of the MAPKs/NF-κB/c-Fos pathways. Journal of Ginseng Research, 2018;42(4) :476-484.
DOI
|
7 |
Carvalho TC, Peters JI. Williams RO 3rd, Influence of particle size on regional lung deposition --what evidence is there? International Journal of Pharmaceutics, 2011;406(1-2):1-10.
DOI
|
8 |
DongGuk University. evelopment of a micro aerosol generating technology for drug delivery system. 2020
|